ATE193207T1 - Vorbeugung von verletzungen und degenerationen von photorezeptoren durch neurotrophische faktoren - Google Patents

Vorbeugung von verletzungen und degenerationen von photorezeptoren durch neurotrophische faktoren

Info

Publication number
ATE193207T1
ATE193207T1 AT93905054T AT93905054T ATE193207T1 AT E193207 T1 ATE193207 T1 AT E193207T1 AT 93905054 T AT93905054 T AT 93905054T AT 93905054 T AT93905054 T AT 93905054T AT E193207 T1 ATE193207 T1 AT E193207T1
Authority
AT
Austria
Prior art keywords
degeneration
injury
prevention
photoreceptors
neurotrophic factors
Prior art date
Application number
AT93905054T
Other languages
English (en)
Inventor
Matthew M Lavail
Roy H Steinberg
George D Yancopolous
Original Assignee
Regeneron Pharma
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma, Univ California filed Critical Regeneron Pharma
Application granted granted Critical
Publication of ATE193207T1 publication Critical patent/ATE193207T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2093—Leukaemia inhibitory factor [LIF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Electrotherapy Devices (AREA)
  • Control Of Combustion (AREA)
  • Eye Examination Apparatus (AREA)
  • Bidet-Like Cleaning Device And Other Flush Toilet Accessories (AREA)
AT93905054T 1992-02-14 1993-02-12 Vorbeugung von verletzungen und degenerationen von photorezeptoren durch neurotrophische faktoren ATE193207T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83609092A 1992-02-14 1992-02-14
US89730792A 1992-06-11 1992-06-11
PCT/US1993/001328 WO1993015608A1 (en) 1992-02-14 1993-02-12 Prevention of retinal injury and degeneration by specific factors

Publications (1)

Publication Number Publication Date
ATE193207T1 true ATE193207T1 (de) 2000-06-15

Family

ID=27125846

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93905054T ATE193207T1 (de) 1992-02-14 1993-02-12 Vorbeugung von verletzungen und degenerationen von photorezeptoren durch neurotrophische faktoren

Country Status (10)

Country Link
EP (1) EP0671879B1 (de)
JP (1) JP3645902B2 (de)
CN (1) CN1077799C (de)
AT (1) ATE193207T1 (de)
AU (1) AU677951B2 (de)
CA (1) CA2130115C (de)
DE (1) DE69328730T2 (de)
HK (1) HK1008292A1 (de)
IL (1) IL104726A (de)
WO (1) WO1993015608A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166317A (en) * 1988-10-31 1992-11-24 Houston Biotechnology Incorporated Neurotrophic factor
US6780837B1 (en) 1989-08-30 2004-08-24 The Regents Of The University Of California Prevention of retinal injury and degeneration by specific factors
GB9203533D0 (en) * 1992-02-19 1992-04-08 Erba Carlo Spa Use of the conjugate between a fibroblast growth factor and a saporin in treating ocular pathologies
AU7568094A (en) * 1993-08-12 1995-03-14 Cytotherapeutics, Inc. Improved compositions and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules
US6750196B1 (en) * 1995-03-27 2004-06-15 Acorda Therapeutics Methods of treating disorders of the eye
US5641750A (en) * 1995-11-29 1997-06-24 Amgen Inc. Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (GDNF) protein product
US5641749A (en) * 1995-11-29 1997-06-24 Amgen Inc. Method for treating retinal ganglion cell injury using glial cell line-derived neurothrophic factor (GDNF) protein product
US6261545B1 (en) * 1996-09-13 2001-07-17 Advanced Medicine Research Institute Ophthalmic compositions of neurotrophic factors, remedies for optic nerve function disorders and method for treating optic nerve function disorders
DE19718826A1 (de) * 1997-05-05 1998-11-12 Marion S Dr Eckmiller Verwendung biologisch aktiver Wirkstoffe zum Beeinflussen des Extrazellulär-Raumes von Sinneszellen und Verfahren zur Wirkstoff-Administrationssteuerung
WO2000068267A1 (en) * 1999-05-06 2000-11-16 The Schepens Eye Research Institute, Inc. LOW-DOSE IL-1β-INDUCED PHOTORECEPTOR CELL RESCUE WITHOUT RETINAL DYSPLASIA
CN113069533A (zh) * 2021-03-08 2021-07-06 温州医科大学 一种长效成纤维细胞生长因子凝胶

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ233071A (en) * 1989-03-30 1993-02-25 Sumitomo Pharma Neurotrophic peptides, extraction from mammalian hippocampal tissue and pharmaceutical compositions thereof
US5260059A (en) * 1989-04-14 1993-11-09 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon Health Sciences University Treatment of open-angle glaucoma by modulation matrix metalloproteinases and their inhibitor
US5229500A (en) * 1989-08-30 1993-07-20 Regeneron Pharmaceuticals, Inc. Brain derived neurotrophic factor

Also Published As

Publication number Publication date
JPH07507053A (ja) 1995-08-03
CA2130115A1 (en) 1993-08-19
EP0671879A1 (de) 1995-09-20
AU3619493A (en) 1993-09-03
WO1993015608A1 (en) 1993-08-19
IL104726A (en) 2000-07-26
DE69328730D1 (de) 2000-06-29
CA2130115C (en) 2004-09-14
AU677951B2 (en) 1997-05-15
JP3645902B2 (ja) 2005-05-11
EP0671879B1 (de) 2000-05-24
HK1008292A1 (en) 1999-05-07
CN1080188A (zh) 1994-01-05
IL104726A0 (en) 1993-06-10
EP0671879A4 (de) 1996-01-17
CN1077799C (zh) 2002-01-16
DE69328730T2 (de) 2000-09-28

Similar Documents

Publication Publication Date Title
ATE193207T1 (de) Vorbeugung von verletzungen und degenerationen von photorezeptoren durch neurotrophische faktoren
ATE190496T1 (de) Behandlung von autoimmunkrankheiten durch verabreichung von autoantigenen in form von aerosol
MX9204381A (es) Metodo para tratar inflamacion ocular
DE122006000010I2 (de) Benzocyclobutyl- oder Indanyl-Alkyl-Amino-Alkyl substituierte 3-Benzazepin-2-ones, verwendbar in derBehandlung von kardiovaskularen Krankheiten
DK447788A (da) Apparat til applikation af implantater
ATE319474T1 (de) Behandlung von autoimmunkrankheiten durch orale verabreichung von autoantigenen
DK549189D0 (da) Galanthamin-analoge samt anvendelse af disse til fremstilling af laegemidler til behandling af alzheimer's syge
DE69231644D1 (de) Verwendung von makrolid-verbindungen gegen augenerkrankungen
ATE192931T1 (de) Morphogen-induzierte modulation von entzündlichen antworten
DK230590A (da) Sproejte til brug ved kataraktkirurgi
ATE109001T1 (de) Mittel zur stimulierung der tränensekretion.
FR2343267A1 (fr) Filtre de protection contre les rayonnements, notamment pour la pigmentation directe par exposition au soleil
DK0413329T3 (da) 5-methyl-isoxazol-4-carboxylsyreanilider og 2-hydroxyethyliden-cyaneddikesyreanilider til behandling af øjensygdomme
DE69131398T2 (de) Verwendung von 5-ht4 rezeptorantagonisten zur behandlung von vorhof-fibrillation und zur vorbeugung von schlaganfall
Crozier et al. Photic stimulation of young rats
ATE59778T1 (de) Verwendung von sulfonamidderivaten zur herstellung eines antivirusmittels.
NO170661C (no) Anordning for behandling av yngel paa tidlige utviklingsstadier
ATE82850T1 (de) Verwendung von 2-pyrimidinyl-1-piperazinderivaten.
ATE70181T1 (de) Verwendung von oxochinazolinderivaten bei der behandlung von hyperurikaemie.
KR920700044A (ko) 눈의 동공수축을 유도 및 방지하기 위한 방법 및 수단
Anderson Prior shock trauma and test-shock intensity as determinants of escape learning
SE8303729D0 (sv) Terapeutiskt medel for behandling av allergiska sjukdomstillstand, immunkomplexsjukdomar och tumorer
RU2030908C1 (ru) Способ лечения начальных катаракт и устройство для его осуществления
SU85042A1 (ru) Клей дл приклеивани мелких протезов к телу человека и дл использовани при операци х по пересадке кожи
Bernhardson Intra-maze cues and alternation after forced trials

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties